Abstract 373P
Background
Head and neck squamous cell carcinoma (HNSCC) is a common cancer worldwide with high mortality rates. Studies suggested the incidence of HNSCC will increase by approximately 30% by 2030. However, elderly patients with advanced HNSCC often face challenges in receiving sufficient treatment because of their lower tolerance to therapy. Exploring different approaches for HNSCC is crucial given the world's aging population.
Methods
The study between 2010 and 2021 involved patients with HNSCC located in the oral cavity, oropharynx, larynx, and hypopharynx. The research was focused on advanced-stage patients aged 70 or older. The data were collected from a cancer registry database at a referral institution. The Kaplan-Meier method was used to estimate overall survival (OS).
Results
The study included 1144 patients with HNSCC, of whom 207 (18.1%) were above 70 years old. Over 50% of the patients had advanced disease without metastasis, being stages III, IVA and IVB. The median OS for geriatric patients with advanced disease was 16.1 months. Patients who underwent curative-intent surgery, radiotherapy, or chemoradiotherapy had better survival rates than those who did not (log-rank test: all p < .01). Furthermore, patients with a higher body mass index (≥ 18.5) had improved OS (p = .03). No significant differences were observed in OS between geriatric patients who received systemic therapy or not. By the multivariate analysis, patients who underwent surgery demonstrated higher survival rates, while those with tumors located in the hypopharynx showed inferior outcomes. The median OS was 29.9 and 8.4 months, respectively (p < .01 and p = .01). Table: 373P
AJCC stage III and IV (M0) head and neck cancer (p < .01)
≥ 70-year-old patients | Number | 3-year survival rate |
Withoout curative surgery | 62 | 22.6% |
With curative surgery | 44 | 45.5% |
Conclusions
Geriatric patients with locally advanced HNSCC have a poor prognosis especially for hypopharyngeal cancer. The study suggests that curative surgery may be a beneficial treatment for these patients. However, further research is warranted to optimize treatments and improve outcomes and quality of life for this vulnerable group.
Clinical trial identification
Editorial acknowledgement
The authors would like to thank all colleagues who contributed to this study. The work was supported by the medical integration database of National Taiwan University Hospital and National Taiwan University Hospital Yunlin branch.
Legal entity responsible for the study
Y.T. Liu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract